Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $51,306.08 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $51,306.08. Following the completion of the transaction, the senior vice president now directly owns 4,232 shares of the company’s stock, valued at $204,067.04. The trade was a 20.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Trading Up 3.3 %

Shares of MIRM traded up $1.62 during mid-day trading on Tuesday, hitting $50.21. The company had a trading volume of 410,214 shares, compared to its average volume of 511,828. The business’s 50-day simple moving average is $44.39 and its 200-day simple moving average is $42.02. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $50.34. The stock has a market cap of $2.41 billion, a PE ratio of -24.86 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.57) earnings per share. Sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. boosted its holdings in Mirum Pharmaceuticals by 1.2% in the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after purchasing an additional 75,000 shares during the period. State Street Corp raised its position in Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Geode Capital Management LLC raised its position in Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after acquiring an additional 29,017 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at about $28,913,000. Finally, Loomis Sayles & Co. L P purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at about $19,473,000.

Wall Street Analyst Weigh In

Several research firms have weighed in on MIRM. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Leerink Partners boosted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.